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Objectives: To analyze the implementation of Medicaid preferred drug lists (PDLs) in a 
number of states and determine its impact on quality of care and cost relative to other segments 
of healthcare.
Methods: We reviewed research and case studies found by searching library databases, primarily 
MEDLINE and EBSCOHost, and searching pertinent journals. Keywords initially included 
“drug lists,” “prior authorization,” “prior approval,” and “Medicaid.” We added terms such as 
“inﬂ  uence use of other healthcare services,” “quality of care,” and “overall economic impact.” 
We mainly used primary sources.
Results: Based on our literature review, we determined that there are a number of issues 
regarding Medicaid PDLs that need to be addressed. Some issues include: (a) the potential for 
PDLs to inﬂ  uence the utilization of other healthcare services, (b) criteria used by Medicaid 
for determining acceptance of drugs onto a PDL, (c) the effect of PDL implementation on 
compliance to new regimens, (d) the potential effects of restricting medication availability on 
quality of care, (e) administrative costs associated with PDLs, and (f) satisfaction rates among 
patients and medical providers. This review highlighted expected short-term cost savings with 
limited degree of compromised quality of PDL implementation, but raised the concern about 
the potential long-term decline in quality of care and overall economic impact.
Conclusions: The number of concerns raised indicates that further studies are warranted 
regarding both short-term cost beneﬁ  ts as well as potential long-term effects of Medicaid PDL 
implementation. Objective analysis of these effects is necessary to ensure cost-effectiveness 
and quality of care.
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Over the past decades, the costs associated with healthcare in the United States have 
steadily increased. In 2002, the Center for Medicaid and Medicare Services (CMS) 
found that the US spends nearly $1.6 trillion toward healthcare, which was almost 
15% of the gross domestic product (Mattera 2004). In response to the ever-increasing 
costs associated with healthcare, many policies were initiated through the years; one 
such policy at the state level is utilization of a preferred drug list (PDL) as part of the 
Medicaid Preferred Drug Program (PDP). A PDL is a list of medications that Medicaid 
will cover the cost for without the need to request a prior authorization (PA). PDLs 
are comprised of medications that either are generic formulations or are the result of 
price negotiations between the pharmaceutical companies and Medicaid. Because of 
the cost savings, physicians in most states are required to either prescribe medications 
on the PDL or receive prior authorization to do otherwise (Gencarelli 2003).
To date, approximately 33 states in the nation have implemented the use of PDLs as 
a part of their Medicaid programs (Silow-Carroll and Altera 2004). In New York State, 
this policy has been proposed continuously since 2003–2004 under the expectation that 
it would curb runaway Medicaid costs, thereby saving taxpayers and the government Vascular Health and Risk Management 2008:4(2) 404
Ovsag et al
money. However, many physicians, pharmaceutical compa-
nies, patients, advocates, senators, and assembly members 
opposed the bill (Martinez 2003; Seay 2004). Their concerns 
focused on the possibility that, in the pursuit of short-term 
decreases in costs by limiting drugs offered to patients, Med-
icaid might actually be increasing the long-term costs that 
would accrue; costs due to increased hospitalization because 
of ineffective or suboptimal therapy and the increased ﬂ  ow of 
paperwork due to authorization requests. Thus, there would 
be decreased quality of care further down the line.
The healthcare budget crisis, which is pervasive through-
out the country, has prompted many states to look for ways 
to decrease prescription drug spending. One method used 
by Medicaid for cost-cutting purposes is required rebates 
or discounts. According to federal law, pharmaceutical 
companies must provide prescription drugs to Medicaid at 
a discounted price (Hamel and Epstein 2004). Many states 
have also pooled their resources and collective inﬂ  uence 
together to achieve supplemental rebates beyond the federal 
requirement from a number of drug companies. Some propo-
sitions for cutting Medicaid costs have come from taking a 
cue from managed care organizations (MCOs). In addition 
to such rebates, Medicaid can also keep costs low by cost 
sharing. This concept offers a tiered co-payment system so 
that beneﬁ  ciaries pay a certain fee for their prescription drugs, 
depending on the actual cost of the drugs, thus transferring 
some of the responsibility for cost of prescription drugs to 
the patient. However, such a system is much more feasible 
and much more widely used among private insurers than 
Medicaid. Medicaid beneﬁ  ciaries are much less able to make 
high co-payments (Hamel and Epstein 2004). In addition, a 
study done with a private insurance provider that switched to 
a tiered co-payment system indicated that such a change led 
to signiﬁ  cant discontinuity of treatment, which could jeop-
ardize quality of care (Huskamp et al 2003). If such results 
are seen among patients who have the ﬁ  nancial ability to pay 
higher co-payments, then one could reasonably expect more 
of the same for patients in the Medicaid community, where 
such ﬁ  nancial abilities are hindered (Gleason et al 2005). For 
example, three to ﬁ  ve different medications might be required 
for effective management of hypertension. Increasing the 
patient co-payment would compromise the quality of care in 
certain cases attributed to the issue of affordability.
Use of drug restrictions or PDLs is another attempt at 
cost-cutting techniques within healthcare. Drug restrictions 
are given various names, depending on how strict they 
are and who enforces them (ie, Medicaid or MCOs). For 
example, many MCOs use formularies to control drug costs. 
A formulary is a list of medications that an MCO deems to be 
most medically appropriate and cost-effective. If a formulary 
is open, the physicians make the ultimate decision about use 
of formulary or non-formulary drugs. On the other hand, a 
closed formulary does not give such leeway (Carroll 2002). 
If physicians wish to prescribe a non-formulary medication 
in a closed formulary, they must go through a prior approval 
or prior authorization (PA) process in which they must show 
a special need for the non-formulary medication. MCOs use 
these methods to control drug costs by decreasing utiliza-
tion of costly drugs that can be substituted by inexpensive 
drugs.
Medicaid has adopted PDLs, an idea similar to formular-
ies, which have been implemented in many states, includ-
ing Michigan, Illinois, Louisiana, North Carolina, Maine, 
Florida, and Oregon. The PDL places certain prescription 
drugs on a list, thereby limiting the drugs that physicians 
can prescribe to their Medicaid patients to the “preferred” 
drugs on the PDL. Although the PDL may vary from state 
to state, most PDLs include generic substitutes and less 
costly innovative medications within the same class as more 
expensive ones. Just as with MCOs, physicians can request 
a PA in speciﬁ  c cases in which they believe a patient needs 
an unlisted drug (Curtiss 2003). The idea of the PDL is 
two-fold: ﬁ  rst, it reduces costs by persuading physicians to 
switch, and pharmacists to recommend, prescription drugs to 
equivalent, less expensive drugs that are usually preferred by 
MCOs (Carroll 2002); second, it gives Medicaid the leverage 
it needs to negotiate lower prices, above and beyond rebates 
required federally, with pharmaceutical companies that want 
to be included in the PDL (Hamel and Epstein 2004).
Factors that inﬂ  uence healthcare 
costs
At face value, such programs seem like a great way to reduce 
healthcare costs, via reduction of drug spending. Neverthe-
less, there are other issues aside from immediate cost reduc-
tions that must be considered. When a change must be made 
in a beneﬁ  ciary’s prescription due to implementation of a 
PDL, there may be other unintended effects such as the uti-
lization of other healthcare services, patient compliance with 
the new regimen, quality of care, physician and patient sat-
isfaction, and associated administrative costs. In this report, 
we will review research studies that examined the impact of 
PDL implementation on healthcare costs as well as quality of 
care. By searching research databases available through the 
Albany College of Pharmacy (ACP) library system, we were 
able to identify relevant journal articles concerning the topic Vascular Health and Risk Management 2008:4(2) 405
Preferred drug lists
at hand. The two databases searched included MEDLINE 
and EBSCOHost. In addition, speciﬁ  c journals including 
The New England Journal of Medicine, American Journal 
of Managed Care, and Journal of Managed Care Pharmacy, 
were speciﬁ  cally searched for publications relating to our 
research question via the journal search tool available through 
the ACP library system. Initially keywords such as “drug 
lists”, “prior authorization”, “prior approval”, and “Medic-
aid” were used to perform our literature search. However, 
once speciﬁ  c factors were established such as utilization of 
other healthcare services, differences in restrictiveness of 
formularies, and overall economic impact, these terms were 
used to run the literature search.
Once articles were collected through the database, they 
were examined to make certain that they were primary 
sources indicating the effects of PDL implementation. If 
they were secondary sources, the primary sources were 
identiﬁ  ed through the works-cited sections of the secondary 
sources; these primary sources were sought out, reviewed, 
and included in our study. After all relevant research was 
gathered, the information was combined to make some 
conclusions as to the effects of PDL implementation on 
healthcare costs and quality of care.
Effect on utilization of other health 
care services
The most common and most studied concern regarding PDLs 
is the idea that medication restrictions may tend to increase 
the utilization of other healthcare services, such as hospital 
and physician visits. The economic burden of such an effect 
is illustrated in Figure 1, which shows the economic impact 
of coronary artery disease. Fifty percent of the cost comes 
from direct management of the disease, and the other Fifty 
percent from indirect costs, including productivity loss, 
morbidity, and mortality. Medications are one of the less 
expensive segments that are part of the direct cost of the 
disease. Decreased quality of care can lead to an increase in 
hospital visits, thus increasing both direct and indirect costs 
through loss of productivity. The use of more efﬁ  cacious 
medication would in turn reduce the number of hospital 
visits thus curtailing one of the most expensive segments of 
the healthcare dollar.
Figure 1 The economic impact of coronary heart disease in the United States (AHA 2000).
Coronary Heart Disease Economic Impacts
Direct Cost $ 55.2 Billion Indirect Cost $ 63 Billion
in the US
2000 Estimated Total Cost = $118.2 Billion
Direct Cost:
-Hospital/nursing home
-Physicians/Other
professionals
-Medication
-Home health/other
medical durables
Indirect Cost:
-Loss of productivity due 
to morbidity or mortalityVascular Health and Risk Management 2008:4(2) 406
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In one study, it was found that Medicaid patients with 
cardiovascular conditions who were restricted by PDLs 
faced a statistically signiﬁ  cant increase in number of outpa-
tient hospital visits six months after PDL implementation, 
in comparison to non-Medicaid patients with cardiovas-
cular conditions who were not restricted by PDLs. In fact, 
Medicaid reimbursement among cardiovascular patients 
in the state increased during the year of the study. It was 
stated in the study that hospital or physician visits were 
taken into account if the primary reason for the visit was 
cardiovascular in nature (Murawski and Abdelgawad 2005). 
The cost analysis performed in this study did show more 
modest results than anticipated due to the small sample 
size and difﬁ  culty in accounting for certain variables. 
The differences-in-differences approach used, however, 
worked to reduce or eliminate bias. The trends seen in this 
study show an importance in the need for more attention 
to the long-term ﬁ  nancial impact of cost cutting through 
PDL usage.
Medical care is often referred to as more of an art than 
a science. This phraseology indicates that medicine is very 
individualized and, in certain classes of medication, no two 
patients may react or respond the same. This phenomenon 
is known as heterogeneity of response. Soumerai (2004) has 
suggested that, based on his extensive research, medications 
that are safer to restrict via a formulary such as a PDL are 
those that have low heterogeneity. This means that a greater 
percentage of patients using the medication for the prescribed 
indication will have the desired response, as seen with H2 
antagonists in the treatment of simple heartburn. Soumerai’s 
implication is that the classes of medication exhibiting high 
heterogeneity should not be restricted because response 
rates are inconsistent, even between drugs in the same class. 
Drugs used to treat certain mental and behavioral illnesses 
are examples of such medications, including antidepres-
sants, antipsychotics, benzodiazepines, and antiepileptics. 
Another study attempted to determine the effects of formulary 
restrictions for selective serotonin reuptake inhibitor (SSRI) 
antidepressants on utilization of other health care services. In 
order to determine this point, it had to be assessed whether 
or not there is interchangeability within the class of SSRIs. 
Results indicate that switching SSRIs causes an increased 
incidence of adverse events and discontinuation of treat-
ment, which is the most detrimental effect and can lead to 
worsening depression, hospitalization, and suicide (Hensley 
and Nurnberg 2001). This shows the high heterogeneity of 
response among patients taking SSRIs and the danger associ-
ated with imposing restrictions on these drugs.
A number of states have already responded to the growing 
concern regarding restricting medications, especially among 
fragile patient populations. In Virginia, the Medicaid PDL 
program excludes antipsychotics and antiepileptics from 
being subject to restrictions. They also have two psychia-
trists on their pharmacy and therapeutics (P&T) committee, 
where drugs are evaluated based on efﬁ  cacy data to deter-
mine whether they will be placed onto the PDL (Finnerty 
2003). Other states – such as New York, Kansas, Iowa, and 
Michigan – have also adopted similar exemptions, with some 
even broadening the deﬁ  nition to include any medication 
intended to treat a mental illness. Other classes of medication 
that certain states prohibit restriction from are HIV/AIDS 
medication, drugs used for the treatment of cancer, and 
antirejection drugs for the treatment of organ and tissue 
transplants (Cauchi et al 2006).
The argument that drug restrictions tend to increase 
utilization of other areas of healthcare merits serious con-
sideration. As drug restrictions start to affect medications 
with high heterogeneity of response, we may begin to see 
an increase in hospital and physician visits. Although many 
states have not restricted certain drugs associated with sensi-
tive populations, it was discovered that the cost savings after 
PDL implementation were not as much as desired. This may 
lead some states to rescind their exclusions in order to save 
more money, as was attempted in Oregon (Bernasek et al 
2004). It is yet to be determined what effect these possible 
changes would have on spending and utilization in other areas 
and on the overall health of its beneﬁ  ciaries.
Criteria used for acceptance of drugs 
onto a PDL
A main concern among beneﬁ  ciaries of Medicaid under new 
PDL programs has been whether their medications will be 
covered. State Medicaid departments have assured their ben-
eﬁ  ciaries that the drugs approved for coverage are the best 
medications in their respective classes, taking both safety and 
efﬁ  cacy into account well before cost considerations. It has 
been shown, however, that there are many factors involved 
in the lengthy process of determining the “preferred status” 
of a medication.
States that have implemented the use of a PDL have all 
followed the same general courses of action. A P&T commit-
tee, made up of physicians, pharmacists, nurses, and others, 
is appointed to determine which classes of drugs are to be 
evaluated for inclusion to the PDL. At this point, pharmacy 
beneﬁ  t managers (PBMs) are often contracted to negotiate 
supplemental rebates (beyond the federally mandated rebates) Vascular Health and Risk Management 2008:4(2) 407
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with manufacturers of the drugs in question on behalf of the 
state. Manufacturers will undoubtedly grant rebates to state 
Medicaid programs in order to ensure that their drug products 
will be more closely considered for the state’s PDL. Inclu-
sion on such a list would guarantee a generous percentage 
of the state’s population who will be utilizing their drug. 
Some states have even come together to form coalitions to 
increase their purchasing power and negotiation leverage 
with manufacturers. In many cases, those manufacturers who 
have not negotiated price rebates will not have their drugs 
considered for inclusion (Texas Health and Human Services 
Commission 2005).
After rebates are negotiated, the P&T committees review 
information acquired from manufacturers, labelers, and other 
parties. They also consider public testimonies. Safety, efﬁ  -
cacy, and clinical outcomes of each considered medication 
are reviewed publicly. Cost considerations and ﬁ  nal recom-
mendations are made behind closed doors due to regulations 
that allow manufacturer price negotiations to remain private. 
The P&T committee then announces its recommendations 
publicly to be approved by the state Medicaid agency (Texas 
Health and Human Services Commission 2005). In most 
states, medications that do not make it onto the PDL are 
considered “non-preferred”; prior authorization must be 
obtained for them to be covered by Medicaid.
It is well documented that the P&T committees and sub-
committees entrusted with evaluating medical information 
do not take their job lightly. Subcommittee reports on single 
classes of medication are lengthy and ﬁ  lled with clinical trials 
and other documentation evaluating therapeutic outcomes, 
adverse events, and safety in numerous patient populations. 
Nevertheless, there are times that cost considerations come 
before clinical outcomes in the decision-making process. For 
example, the P&T committee of Louisiana announced its 
recommendations for drugs in a number of therapeutic classes 
to be included in the state’s Medicaid PDL. Two very com-
monly prescribed medications, Lipitor (for hyperlipidemia) 
and Norvasc (a calcium channel blocker for hypertension) 
were noticeably absent from the list. It was stated that the 
reason for their absence was that Pﬁ  zer (New York, NY), the 
manufacturer of both medications, had not entered into price 
negotiations with the state (Louisiana Department of Health 
and Hospitals 2005). Both medications have been placed 
as non-preferred drugs regardless of evidence of greater 
therapeutic beneﬁ  t; For example, reduction of low-density 
lipoprotein of Lipitor as compared to most other “statins” 
and evidence of higher overall medical costs associated with 
switching from Norvasc to another medication in the same 
class should have been considered (Jones et al 1998; Smith 
et al 2002). Decisions such as these may result in patients 
receiving suboptimal treatment in favor of a short-term cost 
savings. While P&T committees generally strive to allow 
for availability of the best-quality medications possible for 
Medicaid beneﬁ  ciaries, it seems that cost factors can occa-
sionally win out over safety and efﬁ  cacy.
Effect of PDL implementation 
on compliance to new regimens
Another long-standing issue in the healthcare ﬁ  eld is the 
concern of patient adherence to medication regimens. It is 
believed that fewer than 50 percent of patients in developed 
countries who suffer from chronic conditions are adherent 
to their treatment recommendations (World Health Orga-
nization 2003). Noncompliance to therapy and lifestyle 
modiﬁ  cations in many chronic conditions like hypertension 
can lead to detrimental effects such as stroke, heart attack, 
and heart failure.
There are a number of approaches that we have found 
over the years to minimize the possibility for noncompliance. 
These methods include patient education on the disease state 
and importance of treatment, new formulations of drugs that 
reduce dosing frequency or improve ease of administration, 
and combining medications that are commonly used together 
in order to minimize pill burden. Except for patient education, 
these other methods tend to be newer and more innovative 
than their predecessors are. They are often more expensive 
and less likely to be available to Medicaid patients under a 
restrictive drug formulary.
Drug manufacturers can create extended-release prepa-
rations of their drugs in order to decrease dosing frequency 
and pill burden on a patient; two examples are Toprol XL, 
the extended-release version of metoprolol for hypertension, 
and Effexor XR, an extended-release version of Effexor 
indicated for treatment of depression and anxiety. While 
these formulations help to increase patient compliance, 
they also cost more due to new patents for the brand. In 
Georgia, for example, generic metoprolol is a preferred drug 
on the state’s PDL, but Toprol XL is not covered (Georgia 
Medicaid/PeachCare Preferred Drug List 2006). Similarly, 
in Florida, regular-release Effexor is the favored drug on the 
PDL over Effexor XR (Florida Medicaid Preferred Drug List 
2006). One study conducted on diabetic patients attempted 
to determine the difference in compliance between patients 
taking a once daily versus a twice-daily oral antidiabetic 
drug regimen. The study showed increased compliance and 
improved glycemic control in the once-daily patient group. Vascular Health and Risk Management 2008:4(2) 408
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While the study could not speciﬁ  cally attribute the glycemic 
control to either adherence or therapeutic superiority, there 
is still a clear correlation between dosing frequency and 
general pill burden and therapy adherence (Kardas 2005). 
If states start to utilize therapies that are simpler for patients 
to use, there is a good chance they could avoid incurring 
payments in other areas of healthcare that would be due to 
poor compliance.
Potential effects of medication restriction 
on quality of care
To analyze the potential effects that PDLs and other medica-
tion restrictions may have on quality of patient care, we must 
ﬁ  rst deﬁ  ne good quality of care. Aside from the personal 
responsibilities we have toward our own healthcare, physi-
cians have the ability to evaluate our health status individu-
ally and determine what means of therapy is best, whether 
it be by lifestyle modiﬁ  cations or by medication interven-
tion. The problem comes when external factors inﬂ  uence a 
physician’s judgment toward utilizing therapies that may not 
be best for a particular person. Thus, good quality of care 
may be described when patients receive the type(s) of therapy 
most appropriate to treat their condition.
With more restrictive policies in place for drug approval, 
physicians are more likely to use a different therapy than 
what may be optimal in order to avoid the hassles of receiv-
ing authorization. In Illinois, after PDL implementation, the 
percentage of shares of off-PDL prescriptions dropped from 
13.5 percent to 1.6 percent. In Louisiana, where the approval 
process is much less stringent, there was less of a reduction in 
prescribing for non-preferred drugs (Virabhak and Shinogle 
2005). While this is indicative of the utility of PDLs and strict 
PA processes in reducing spending on non-preferred drugs, 
we must also consider the chance that perhaps the quality 
of therapy was not optimal, because other therapies were 
utilized prior to PDL implementation.
Effects of Medicaid PDL implementation may even be 
seen in the general population due to a phenomenon called 
the “spillover effect.” This is when a physician’s prescrib-
ing behavior is altered, not only for Medicaid patients, but 
also for patients who are not subject to the same formulary 
restrictions. In Illinois, it was observed that among physi-
cians who mainly saw Medicaid patients, who were subject 
to formulary restrictions, there was a signiﬁ  cant drop in the 
writing of non-preferred drugs for those patients who had 
other third party coverage (Virabhak and Shinogle 2005). 
Some third parties adjust their own formularies to mimic 
that of the state Medicaid formulary. Unfortunately, such 
“bandwagon effects” were unexplainable. This example 
indicates the high level of inﬂ  uence that PDLs can have on 
some physicians, which may lead to spillover effects on the 
general population.
Another study determined that physicians who saw 
patients associated with Paciﬁ  Care, a large third-party pro-
vider in Cypress, California, tended to prescribe the same 
drugs for non-Paciﬁ  Care patients as were on the Paciﬁ  Care 
formulary. The observed spillover effects indicate that greater 
restrictions have a tendency to inﬂ  uence a physician’s pre-
scribing patterns universally (Wang and Pauly 2005). There 
are some instances where switching medications within a 
class had no signiﬁ  cant effect on therapeutic outcome. In 
the cases where there is a difference between drugs, how-
ever, there is the possibility for compromised quality of care 
when barriers are in place to dissuade the use of those drugs. 
Whether or not the changes in prescribing patterns lead to 
patients not receiving optimal and personalized treatment, it 
is an issue of great concern that must still be studied.
Administrative costs associated 
with PDLs
There have been questions raised as to whether implementa-
tion of a PDL program for Medicaid will save money because 
of decreased drug spending or if it will cost more money 
because of the administrative burden of processing authori-
zations. Considering the drug rebates that states obtain and 
the effect of formulary restrictions on physician prescribing 
patterns, it is no surprise that states like Iowa have found 
signiﬁ  cant cost savings associated with PDL implementation. 
The Iowa state Medicaid advisory council reported an aver-
age savings of $17.8 million for 2005, and estimates a savings 
of $22 million in 2006 (State of Iowa Department of Human 
Services 2006). The analysis of cost savings neglected to 
mention any administrative costs of the program.
A number of areas must be considered when reviewing 
costs associated with PDL implementation. Firstly, there 
are costs associated with forming and executing P&T com-
mittee meetings; these costs are salaries that are ﬁ  gured into 
the state’s budget. Secondly, there are the costs of contract-
ing PBMs to negotiate rebates with drug manufacturers. 
Lastly, Medicaid must also contract with a PA service that 
will receive authorizations requests, evaluate them, hand 
them off to physicians or pharmacists hired to evaluate these 
more complex requests, and either approve or deny a claim. 
The Texas Medicaid PDL Annual Report stated that their 
administrative cost for contracting both PBM and PA pro-
vider services was about $3.3 million from November 2003 Vascular Health and Risk Management 2008:4(2) 409
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to August 2004. It is now estimated that the PDL program 
will maintain a drug savings of about $140 million for the 
2004–2005 biennium (Texas Health and Human Services 
Commission 2005). This shows that the PDL implementation 
in Texas will bring much more savings in drug spending than 
the cost to administer the program.
State Medicaid agencies have not accounted for the 
administrative costs for other healthcare providers. Both 
physicians’ ofﬁ  ces and pharmacies have noted increases 
in time spent processing authorizations; time that could 
be better spent interacting with patients and reducing 
medication errors. A survey was conducted in Maine that 
indicated that 98 percent of providers reported an increase 
in telephone trafﬁ  c after implementation of the PA program 
(MaineCare Advisory Committee 2005). This, in turn, has 
resulted in an increase in administrative overhead costs and 
provider time constraints. One physician said, “It takes too 
much time to ﬁ  ll out forms and that time could be spent 
returning patient calls and reaching patients.” Similarly, 
another provider indicated, “[the PA process] requires 
additional staff to meet the paper work needs. Ten to ﬁ  fteen 
hours weekly are spent ﬁ  ling PA’s, on the phone with GHS 
staff, and combing through charts for the increasing amount 
of information demanded to get PA’s approved.” While 
the direct administrative costs do not seem to outweigh the 
savings associated with decreased drug spending, the effect 
on administration in other areas of healthcare should also 
be considered.
Patient and provider satisfaction 
with PDL programs
There has been much controversy surrounding the imple-
mentation of PDLs in states throughout the country. Many 
healthcare providers and patient advocates are concerned 
that drug preference will go to the lowest bidding manufac-
turer as opposed to the most effective and safest medication. 
In New York State, the proposed PDL bill did not even 
pass legislation until there was a safeguard for all medica-
tions prescribed for mental illness, HIV/AIDS, cancer, and 
organ and tissue transplantation. While different states are 
implementing different policies, most will still be utilizing 
the PA method to deter usage of higher-cost medications. 
Many healthcare providers have issues with mandatory 
PAs and are becoming frustrated. One provider in Maine 
remarked, “Our practice is considering limiting the number 
of Medicaid patients; other surrounding practices have done 
so and [their patients] are now ﬂ  ooding into our ofﬁ  ce” 
(MaineCare Advisory Committee 2005). Such decisions to 
limit Medicaid patients would greatly decrease the access 
such patients would have to healthcare and may deter them 
from seeking preventative care. This may cause them to 
end up in an emergency room and incur greater expenses. 
Despite the push for preventative healthcare today, it seems 
the PDL’s effects on providers may result in less preventa-
tive care and more chronic medical issues, which are more 
costly in the long run.
In addition, the conﬂ  ict between quality and costs is 
inevitable when decisions must be made between clinical 
and management goals, it disrupts the doctor-patient rela-
tionship. Patients believe more and more that physicians no 
longer have a duty to deliver quality care. With concepts of 
salary bonuses for those who provide the most inexpensive 
care and cuts for those who provide costly care, there is a 
conﬂ  ict of interest that the patients can sense (Avorn 2002). 
PDLs and formularies continue to bring such conﬂ  icts into 
the examination room and push patients further and further 
from their physicians. This is not to say physicians should 
not be cost conscious; on the contrary, physicians have a 
responsibility to be aware of the economic consequences of 
their clinical decisions, but during this process, the insur-
ers, employers, payers, and others should not push them in 
numerous directions.
There are known impacts of formulary restrictions on 
patient satisfaction across many third-party payers. For 
MCOs, this can be a large problem; their business is depen-
dent on providing insurance to patients, without patients, 
there is no business. Even in the arena of PA for referrals and 
medical procedures, many MCOs found themselves dropping 
PAs due to the high administrative costs and low patient 
satisfaction. For example, UnitedHealth dropped its require-
ments after ﬁ  nding that they denied fewer than 2 percent of 
treatment requests (Curtiss 2002). Within the next year, the 
organization had saved $110 million in administrative costs 
and experienced a 26 percent decrease in member complaints 
as well as a 21 percent growth in membership the following 
year. Blue Cross of California experienced similar beneﬁ  ts 
after dropping their PA program. Though loss of members 
is not an issue in the Medicaid program, they should still 
be concerned with patient satisfaction as well as decreasing 
administrative costs.
In Maine, there have been numerous cases of patient 
dissatisfaction since the implementation of a PA pro-
gram for prescription drugs for the elderly in 2001 
(MaineCare Advisory Committee 2005). For example, 
one patient suffered from multiple chronic conditions, 
including severe osteoarthritis, hypothyroidism, chronic Vascular Health and Risk Management 2008:4(2) 410
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renal failure, chronic lower back pain, type II diabetes, 
hypertension, severe dementia, and depression. She 
began using OxyContin® (Purdue Pharma L.P., Stamford, 
CT) for pain management in 1999. Her treatment was 
discontinued. When her doctor submitted a request for PA 
for OxyContin® in March 2004, the Department of Health 
and Human Services for the MaineCare Program denied it, 
claiming that the patient had to try as many as nine different 
pain medications before the PA for OxyContin® could be 
approved. An appeal of the denial of the PA was made on 
behalf of the patient, but she passed away before a decision 
was made. Another patient suffering from attention deﬁ  cit/
hyperactivity disorder was denied coverage of Provigil® 
(Cephalon, Frazer, PA) because of the PA program. Even 
one year after the PA was requested, the case was still in 
the appeal process. Each state’s Medicaid PDL program 
varies slightly with regard to certain requirements before 
approval can be made for a restricted drug. Some require-
ments are much more lenient, such that there needs only to 
be documentation of previous success on the medication or 
previous failure of the preferred drug. In either situation, 
the hurdles involved in obtaining a desired “non-preferred” 
medication represent an annoyance at best and a health risk 
at worst to the patient.
Recommendations for cost 
containment
In consideration of all these facts, one assumes that there 
must be a large advantage, as far as cost reduction, in 
implementing PDLs. However, prescription drugs comprised 
only 11 percent of the Medicaid budget in 1999. A greater 
percentage of the expenditures were allocated toward insti-
tutional long-term care, and inpatient and outpatient hospital 
visits (29 percent and 19 percent, respectively) (Rudolph and 
Lubitz 1999). Figure 2 shows approximately how much of 
each dollar was being spent in each segment of healthcare 
for Medicaid in 2002; this illustrates the small part that 
drug spending has played in the Medicaid budget. A study 
conducted by Strunk et al (2002) commented that in 2001, 
despite the 12 percent increase in healthcare spending per 
capita, this increase reﬂ  ected a greater use of hospital services 
as well as an increase in hospital payment rates. In fact, in 
2001 – as was seen in 2000 – prescription drug spending 
growth declined. Therefore, an economic evaluation seems 
Figure 2 Illustration of the approximate cost of each segment in the health ﬁ  eld expressed as a percentage of the nation’s health dollar (Health Care Financing Administration 2004). 
1Includes dental services, other professional services, home health, durable medical products, over-the-counter medicines and sundries, public health, research and construction.Vascular Health and Risk Management 2008:4(2) 411
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necessary to judge whether cost-cutting tactics in the area of 
pharmaceuticals, such as PA, are the most beneﬁ  cial.
It seems that the approach of merely limiting prescription 
drugs in order to alleviate a budget deﬁ  cit in Medicaid is illogi-
cal. In contrast, every component of the healthcare industry 
should be reviewed as part of reducing healthcare costs. Though 
a decrease in pharmaceutical costs may seem like a great place 
for cost containment due to the ability to see direct changes 
in drug sales, medications are the most cost-effective means 
of treating chronic illnesses. Therefore, use of the healthcare 
budget toward pharmaceuticals may be more effective than 
using that money in other areas such as hospital stays.
Medications and lifestyle modiﬁ  cations are the best forms 
of prevention for cardiac diseases such as stroke and heart 
attack. Figure 3 illustrates the cumulative cost of strokes 
in this country. The economic impact of such diseases is 
tremendous, with the bulk of the cost being associated with 
hospital stays, nursing home placement, and the indirect cost 
of morbidity and mortality. These segments alone comprise 
about 89 percent of the cost of the disease. Even if spending 
for drug treatment were to increase, the subsequent reduc-
tion in other segments would be well worth the cost, both 
economically and individually.
To further illustrate that prescription drugs are one of the 
most effective and least expensive segment in healthcare, 
Lichtenberg (2005), as mentioned in Bussing-Burks (2006), 
did a study that indicated that replacing 1000 old prescrip-
tion drugs with 1000 new prescription drugs resulted in drug 
costs increasing by $18,000 with hospital costs decreasing 
by $44,469. Lichtenberg’s data was obtained via the 1996 
Medical Expenditure Panel Survey. This study provides data 
that conﬁ  rms that drug age inﬂ  uences effectiveness, resulting 
in changes in medical expenses.
With most states in the country implementing PDLs 
or some other form of drug spending containment in their 
Medicaid programs, there must be a balance maintained 
Figure 3 The estimated cost of stroke in the United States (AHA 2000).
Estimated Cost of Strokei nt h eU S
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Lost productivity due to
mortality, $15.1
Home health/Other medical
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Drugs, $0.4
Physician/Other
Professional, $2.3 Indirect Cost = $20.7 Billion
-Lost productivity due to morbidity
-Lost productivity due to mortality
Total Cost = $51.3 Billion
Direct Cost = $30.6 Billion
-Hospital/Nursing Home
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between cost savings and providing good quality and timely 
medical care. This has proven to be a difﬁ  cult task, with 
some states being forced to abandon their desires to have an 
unrestricted formulary due to critical budget crises. New York 
State, for example, has consistently offered many optional 
programs such as psychiatric services, podiatry services, and 
many more to Medicaid beneﬁ  ciaries. In turn, New York 
spends more money on Medicaid services than the states of 
California and Texas combined (Center for Governmental 
Research, Inc. 2004). Oregon has implemented a Practitio-
ner-Managed Prescription Drug Plan (PMPDP) where the 
PDL is only a guide as to which drugs strike the best balance 
between therapeutic beneﬁ  t and cost-effectiveness; its usage 
is entirely voluntary (Bernasek et al 2004). While this is an 
excellent way to ensure that practitioners retain autonomy 
in treating their patients, it has not proven to have the best 
impact on cost containment.
It appears that the ideal PDL program would be one that 
has identiﬁ  ed the most cost-efﬁ  cient therapies in classes of 
medication with therapeutic responses that are practically 
universal and repercussions minimal. In sensitive conditions 
and in those classes where there is high heterogeneity of 
response, cost-efﬁ  cient medications should be highlighted, 
for informational purposes, but not mandated. Physicians 
should be able to make the best decisions for each individual 
patient, and be able to switch medications if necessary by 
simply stating so on the prescription as opposed to perform-
ing an arduous and time-consuming PA request that leaves 
the physician, the pharmacy, and the patient frustrated. One 
example of such a policy is seen in the Medicaid program of 
Alaska. Preferred drugs and generics are available without 
authorization. Other “non-preferred” drugs require only a 
statement of medical necessity on the prescription in order 
to be covered, similar to a dispense as written (DAW) des-
ignation (Preferred Drug List Program 2006). Voluntary 
lists encourage the use of cost-effective medications but do 
not dissuade practitioners from utilizing any therapy that 
may be medically necessary. At this time, there has been 
no statement released on the state’s costs and savings after 
program implementation.
Healthcare cannot be managed in a short-term mindset, 
and decisions should not be made without looking at their 
reverberations in the future. Nevertheless, our actions within 
the healthcare industry have repeatedly shown that we focus 
on short-term beneﬁ  ts in many of our decisions. Examples 
of such concern for the short-term costs are rampant in 
healthcare because there may be one component responsible 
for a large portion of the bill. However, in the end, some 
“quick-ﬁ  x” cost-saving policies may not always be the most 
beneﬁ  cial ones, economically. We are beginning to see the 
effects in the Medicare Part D drug plan, where seniors 
who have found themselves in a “doughnut hole” are now 
paying full price for their medications. This has shown to 
decrease compliance and usage of medication, which can 
clearly be detrimental, especially in patients with chronic 
diseases (Stuart et al 2005). It remains to be seen how the 
PDL programs implemented around the country will affect 
the Medicaid population.
Conclusion
The studies and literature we have examined illustrate that 
there are a number of issues to be considered concerning 
the implementation of a PDL in a state Medicaid program. 
Some key issues include the effects on use of other health-
care services, the criteria used by P&T committees for 
acceptance of drugs onto a PDL, the effect of switching 
medication therapy on patient compliance, the possible 
effects of drug restriction on quality of care, the administra-
tive costs associated with the program, and the impact such 
reforms may have on physician and patient satisfaction. 
Reducing drug spending via PDLs and drug authorizations 
is a common practice in most states, and is an effective 
way to save money. The best way to approach reforms in 
Medicaid policies, however, is to consider the effects that 
such programs will have on the future of healthcare and 
reinforce the importance of proper prescription drug use 
in improving health outcomes. Issues concerning conﬂ  icts 
between cost savings and quality of care illustrate the need 
for more studies on cost expenditures of open and closed 
formularies that also analyze all aspects of the subsequent 
quality of care received.
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